Paliperidon Starterpackung Genericon (Paliperidone Palmitate)

Paliperidone palmitate acts as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors. By blocking D2 receptors in key brain pathways it diminishes positive psychotic symptoms, while 5‑HT2A antagonism balances dopamine activity and reduces motor side effects. The palmitate ester forms a depot that releases the drug slowly over weeks.

The exact dosing regimen is determined by the prescribing clinician based on the patient’s clinical status, prior response, and tolerability. Doses are individualized and administered as a monthly intramuscular injection according to the product’s prescribing information.

Paliperidone palmitate is classified as a pregnancy category C medication. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended because the drug is excreted in milk and may affect the infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Paliperidone palmitate offers once‑monthly dosing similar to other depot formulations like risperidone microspheres or aripiprazole monohydrate. Its receptor profile provides strong D2 antagonism with additional 5‑HT2A blockade, which may result in a different side‑effect balance, particularly regarding prolactin elevation and metabolic effects.

The product must be stored refrigerated at 2‑8 °C. Keep it in the original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as stability may be compromised.

Paliperidon Starterpackung Genericon is given as an intramuscular injection, typically into the deltoid or gluteal muscle. The injection is performed by a qualified healthcare professional using aseptic technique. The dosing interval is usually once every four weeks after the initial loading phase.

Serious adverse events include neuroleptic malignant syndrome, tardive dyskinesia, seizures, and significant orthostatic hypotension. Patients should be monitored for signs of fever, muscle rigidity, involuntary movements, or sudden drops in blood pressure, and the medication should be discontinued if these occur.

Patients with known hypersensitivity to paliperidone, its excipients, or any component of the formulation should avoid use. Caution is also advised for individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome.